BC Platforms has launched BC Catalyst, a first-of-its-kind AI-native platform that transforms complex genomic and real-world clinical data into actionable insights across the full drug lifecycle.
By unifying discovery, development and real-world evidence, BC Catalyst utilises agentic AI to identify patient cohorts, uncover drug targets, analyse genetic variants and generate insights on standards of care.
The industry must accelerate development, cut costs and raise a ten per cent market entry success rate.
Yet innovation is held back by fragmented and siloed multimodal data, from genomics to real-world evidence, that remains incomplete and difficult to use.
The development of more targeted therapies has also been hindered by a lack of research-ready, actionable data that reflects the diverse genetic makeup of various geographic ancestries and ethnicities around the globe.
BC Catalyst overcomes these challenges by making it fast and easy for researchers to query and analyse data that has been integrated, harmonised and made ready to use in a highly intuitive, prompt-based interface.
The platform helps life sciences companies design more personalised and precise medicines, such as tumour-agnostic therapies, while accelerating discovery, optimising clinical trials and guiding commercial decisions through to product launch and market uptake.
Available by subscription, BC Catalyst utilises a proprietary AI and high-performance computing architecture that continues to learn and grow as queries are executed on rich, granular data.
Through the convergence of global genomic, clinical and real-world evidence, BC Catalyst answers the growing demand for biomarker-based, patient-specific insights.
"BC Catalyst sits at the intersection of precision medicine and enterprise-scale biopharma intelligence, representing a monumental shift in the speed and manner in which new medicines can be discovered, developed and brought to market," said Mukhtar Ahmed, CEO, BC Platforms.
"With this new offering, we are responding to the industry's unmet need for precision and personalisation through integrated, scalable solutions that eliminate current siloed approaches and inefficiencies, facilitate better and faster decision-making and propel healthcare innovation."
Keith Collier, Chief Product Officer, BC Platforms, added: "Obtaining actionable insights that apply the full depth and breadth of global real-world and genomic data has not, until now, been commercially viable."
"BC Catalyst unlocks the true potential of agentic AI, high-performance computing and advanced machine learning to support a wide spectrum of use cases, especially in underserved areas such as precision oncology."
"It can help researchers better understand treatment patterns, uncover novel insights and identify new ways to address the global burden of different diseases."
BC Catalyst utilises data that has been anonymised, harmonised and integrated in BC Unify, the company's data mastering platform that ingests, transforms and enriches multi-modal data to make it research-ready to support clinical and commercial decisions.
BC Unify incorporates proprietary AI-powered data processing, structuring and integration workflows, coupled with automated quality checks and mapping capabilities, to bring together diverse data sets from BC Platforms' global network of more than 150 partners and patient catchment of more than 130 million lives.
Building on its architectural foundation, BC Catalyst will continue to expand its capabilities across the drug lifecycle to include post-launch intelligence, real-world outcomes and evidence-based care.
These enhancements will deliver measurable ROI, scalable insights and differentiated value for pharmaceutical, biotech and med tech organisations as they develop and launch new precision medicine treatments.